ARS Pharmaceuticals (SPRY) Free Cash Flow (2020 - 2026)
ARS Pharmaceuticals (SPRY) reported Free Cash Flow of -$44.9 million for Q1 2026, down 10.07% on a YoY basis from -$50.0 million in Q1 2025, and down 3.36% sequentially from -$43.5 million in Q4 2025.
ARS Pharmaceuticals (SPRY) Free Cash Flow (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals (SPRY) has 7 years of Free Cash Flow data on file, last reported at -$44.9 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 10.07% year-over-year to -$44.9 million; the trailing twelve-month figure through Mar 2026 stood at -$175.3 million (down 732.67% YoY), and the FY2025 full-year result was -$171.2 million, down 1418.48% from the prior year.
- Free Cash Flow eased to -$44.9 million in Q1 2026, from -$43.5 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $41.7 million in Q4 2024 to a low of -$45.4 million in Q2 2025.
- A 5-year average of -$17.8 million and a median of -$14.7 million in 2024 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow soared 338.45% in 2024 and slumped 530.36% in 2025, its largest moves.
- Tracing SPRY's Free Cash Flow over 5 years: stood at -$20.6 million in 2022, then gained by 15.2% to -$17.5 million in 2023, then soared by 338.45% to $41.7 million in 2024, then slumped by 204.28% to -$43.5 million in 2025, then decreased by 3.36% to -$44.9 million in 2026.
- Business Quant data shows SPRY's Free Cash Flow at -$44.9 million in Q1 2026, -$43.5 million in Q4 2025, and -$41.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | ARS Pharmaceuticals | 595.78 Mn | 394.81 Mn | - | -44.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.95 Mn |
| Mar 31, 2026 | -44.95 Mn |
| Dec 31, 2025 | -43.49 Mn |
| Dec 31, 2025 | -43.49 Mn |
| Sep 30, 2025 | -41.53 Mn |
| Sep 30, 2025 | -41.53 Mn |
| Jun 30, 2025 | -45.36 Mn |
| Jun 30, 2025 | -45.36 Mn |
| Mar 31, 2025 | -40.83 Mn |
| Mar 31, 2025 | -40.83 Mn |
| Dec 31, 2024 | 41.70 Mn |
| Dec 31, 2024 | 41.70 Mn |
| Sep 30, 2024 | -14.73 Mn |
| Sep 30, 2024 | -14.73 Mn |
| Jun 30, 2024 | -7.20 Mn |
| Jun 30, 2024 | -7.20 Mn |
| Mar 31, 2024 | -6.79 Mn |
| Mar 31, 2024 | -6.79 Mn |
| Dec 31, 2023 | -17.49 Mn |
| Dec 31, 2023 | -17.49 Mn |